Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul;1(4):146-54.

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology

John L Marshall  1 , Daniel G Haller, Aimery de Gramont, Howard S Hochster, Heinz-Josef Lenz, Jaffer A Ajani, Richard M Goldberg
Affiliations

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology

John L Marshall et al. Gastrointest Cancer Res. 2007 Jul.

Abstract

Chemotherapy agents available for the treatment of stage II and stage III colon cancer have changed substantially since the 1992 National Institutes of Health consensus report recommended that all stage III patients routinely receive adjuvant treatment with 5-fluorouracil/levamisole. Subsequent trials demonstrated superiority of 5-fluorouracil/leucovorin over 5-fluorouracil/levamisole in the adjuvant setting, and the recent addition of oxaliplatin to this regimen has further improved disease-free survival. While stage III colon cancer patients are routinely treated, the use of adjuvant chemotherapy in patients with stage II disease is still a subject of debate. Many trials that are assessing the potential role of biologics in the adjuvant setting will soon be completed. However, identifying molecular prognostic markers that accurately select patients with stage II or III cancers who are at risk of recurrence would be essential to select and individualize therapy.

PubMed Disclaimer

Figures

None
Richard Goldberg, Jaffer Ajani
None
John Marshall
None
Heinz-Josef Lenz
None
Daniel Haller, Richard Goldberg
None
Aimery de Gramont, Howard Hochster
Figure 1
Figure 1
Data from 6-year update of the MOSAIC trial. Overall survival in stage II vs. stage III patients. From de Gramont et al.
See this image and copyright information in PMC

References

    1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2003. Incidence and Mortality Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007. Available at: www.cdc.gov/cancer/nper/uscs/ Accessed June 27, 2007.
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
    1. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425. - PubMed
    1. Greene FL, Balch CM, Fleming ID, et al. ed 6. New York, NY: Springer; 2003. AJCC Cancer Staging Manual.
    1. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936–2943. - PubMed

LinkOut - more resources